Morningstar
•
Feb 13, 2026
Alnylam Pharmaceuticals, Inc.: Alnylam Earnings: Milestone Year as Firm Turned Profitable; Demand for Amvuttra Drives Growth
Summary
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfr
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
Analyst Report: Eli Lilly and Company
Apr 30, 2026
•
LLY
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
